









Markets
/
Stocks
/
nasdaq-chrs
/

Coherus BioSciences Inc

CHRS

View Detailed Chart

0.878USD

-0.062-6.64%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

101.74MMarket Cap

LossP/E TTM



Coherus BioSciences Inc

0.878

-0.062-6.64%

Overview Company Financials

Financials

Intraday

30m

Today

-6.64%

5 Days

-15.60%

1 Month

+8.37%

6 Months

-20.92%

Year to Date

-36.39%

1 Year

-34.98%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 6 analysts

BUY

Current Rating

6.500

Target Price

640.49%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Coherus Oncology Inc

CHRS

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(6)

Neutral(3)

Buy(2)

Indicators

Sell(1)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.009

Neutral

RSI(14)

47.271

Neutral

STOCH(KDJ)(9,3,3)

23.611

Sell

ATR(14)

0.079

Low Volatility

CCI(14)

-71.170

Neutral

Williams %R

81.644

Oversold

TRIX(12,20)

0.996

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.974

Sell

MA10

0.972

Sell

MA20

0.918

Sell

MA50

0.833

Buy

MA100

0.881

Sell

MA200

1.030

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.

Ticker SymbolCHRS

CompanyCoherus BioSciences Inc

CEOMr. Dennis M. (Denny) Lanfear

Websitehttps://www.coherus.com/